Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
Items 401–500 of 754
Chakravarty, N., Senthilnathan, T., Paiola, S. G., Gyani, P., Cario, S. C., Urena, E., Jeysankar, A., Jeysankar, P., Irudayam, J. I., Subramanian, S. N., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14227 · Cited by 19
“SARS-CoV-2 has been shown to cause neuritic degeneration and synaptic loss in neurons, which increases the risk of developing Alzheimer’s disease [55 – 56].”
BackgroundIncreased fMRI signal with age in familial Alzheimer's disease mutation carriers
Braskie, M. N., Medina, L. D., Rodríguez‐Agudelo, Y., Geschwind, D. H., Macías-Islas, M. Á., Cummings, J. L., Bookheimer, S. Y., & Ringman, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.028 · Cited by 22
“These studies have focused almost exclusively on the contributions to brain activity of allele ε4 of Apolipoprotein E (APOE4), the genetic influence that has most consistently been shown to confer an increased risk of developing late onset AD across numerous studies (Bertram and Tanzi, 2008).”
BackgroundThe Rationale for Insulin Therapy in Alzheimer’s Disease
Ribarič, S. (2016) · Molecules · doi:10.3390/molecules21060689 · Cited by 22
“Caucasian heterozygous and homozygous ApoE-ε4 allele carriers have a three to eight-fold increased risk of AD compared to non ApoE-ε4 carriers [8,218,219].”
BackgroundKey biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies
Jamal, R., Shaikh, M. A., Taleuzzaman, M., Haque, Z., Albratty, M., Alam, M. S., Makeen, H. A., Zoghebi, K. A., & Saleh, S. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330500 · Cited by 19
“11,13,14 According to amyloid hypothesis, the abnormal A β accumulation affects neuronal function, synaptic impairment, and neurodegeneration, is depends on the A β protein.”
Nanomedicine against Alzheimer’s and Parkinson’s Disease
Tandon, A., Singh, S. J., & Chaturvedi, R. K. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201021140904 · Cited by 21
Pomilio, A. B., Vitale, A. A., & Lazarowski, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666221003101548 · Cited by 20
Jin, C., Zhang, L., Xian, Y., Liu, X., Wu, Y., Zhang, F., Zhu, J., Zhang, G., Chen, C., Gong, R., et al. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.01.029 · Cited by 19
A genome-wide association study of Alzheimer’s disease using random forests and enrichment analysis
Zou, L., Huang, Q., Li, A., & Wang, M. (2012) · Science China Life Sciences · doi:10.1007/s11427-012-4343-6 · Cited by 21
Inference of Causative Genes for Alzheimer’s Disease Due to Dosage Imbalance
Sekine, M., & Makino, T. (2017) · Molecular Biology and Evolution · doi:10.1093/molbev/msx183 · Cited by 18
Brown, B. M., Huang, M., Karlamangla, A. S., Seeman, T. E., & Kado, D. M. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0277-5 · Cited by 21
“It is estimated that the APOE-ε 4 allele may account for up to half of all sporadic and familial late-onset cases of Alzheimer’s disease, with carriers being at about three to four times as likely to develop Alzheimer’s than non-carriers (2, 3).”
FMR1 genotype interacts with parenting stress to shape health and functional abilities in older age
Seltzer, M. M., Hong, J., Greenberg, J. S., DaWalt, L. S., Baker, M. W., & Rathouz, P. J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32529 · Cited by 18
Therapeutic targets for Alzheimer's disease
Tarditi, A., Caricasole, A., & Terstappen, G. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902865614 · Cited by 18
“Unfortunately, therapeutic approaches based on ApoE4 would involve the restoration of the activity associated with other ApoE variants, an objective difficult to achieve with small organic molecules, thus rendering ApoE4 a complex and poorly tractable target.”
BackgroundInfluentialGiau, V. V., Senanarong, V., Bagyinszky, E., Limwongse, C., An, S. S. A., & Kim, S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s180174 · Cited by 18
“Typically, the mutations adjacent to the N-terminus of the Aβ sequence led to an increased production of all Aβ species, while the ones near the carboxyl terminus led to an increase in the Aβ42/Aβ40 ratio.(2,3) However, the discovery of APP mutations in EOAD launched many functional investigations of APP.”
BackgroundAge-dependent association of KIBRA gene polymorphism with Alzheimer’s disease in Han Chinese
Wang, H.-F., Tan, L., Yu, J., Ma, X., Liu, Q., & Wang, W. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2830-x · Cited by 17
“firmed as a major contributor to this disease in the worldwide scale [3, 4].”
BackgroundSIRT2 polymorphism rs10410544 is associated with Alzheimer's disease in a Han Chinese population
Xia, M., Yu, J., Miao, D., Lu, R.-C., Zheng, X., & Tan, L. (2013) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2013.10.001 · Cited by 18
“Mutations in three genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2) account for the uncommon early-onset familial AD (EOAD) [2].”
BackgroundApolipoprotein E genotyping using PCR-GoldMag lateral flow assay and its clinical applications
Lian, T., Hui, W., Li, X., Zhang, C., Zhu, J., Li, R., Wan, Y., & Cui, Y. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5768 · Cited by 17
“A polymorphism in Apolipoprotein E (ApoE) is one of the most widely studied polymorphisms, and has been considered to be a pre-symptomatic risk predictor for a variety of diseases, including coronary artery disease and late-onset Alzheimer's disease (3,4).”
Fe65: A Scaffolding Protein of Actin Regulators
Augustin, V., & Kins, S. (2021) · Cells · doi:10.3390/cells10071599 · Cited by 20
“However, the link of Fe65 to ApoE, which is a major risk factor of AD, is very obvious [49].”
BackgroundNext Generation Sequencing in Alzheimer’s Disease
Bertram, L. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2627-5_17 · Cited by 19
Self-citationShi, H., Medway, C., Bullock, J. M., Brown, K. S., Kalsheker, N. A., & Morgan, K. (2010) · PubMed · Cited by 22
Contemporary Modeling of Gene × Environment Effects in Randomized Multivariate Longitudinal Studies
McArdle, J. J., & Prescott, C. A. (2010) · Perspectives on Psychological Science · doi:10.1177/1745691610383510 · Cited by 18
“APOE was selected because of its possible role in dementia (see Bäckman, Jones, Berger, Laukka, & Small, 2005; Bertram & Tanzi, 2008) and because it was available on a large portion of the ADAMS sample.”
BackgroundSystems medicine and the integration of bioinformatic tools for the diagnosis of alzheimer's disease
Orešič, M., Lötjönen, J. M. P., & Soininen, H. S. (2010) · Genome Medicine · doi:10.1186/gm204 · Cited by 18
Husain, I., Khan, S. I., Khan, S., Madaan, T., Kumar, S., & Najmi, A. K. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13040 · Cited by 18
Nina, S., Strekalova, E., Djogo, N., Plöger, F., Loers, G., Lutz, D., Buck, F., Michalak, M., Schachner, M., & KLEENE, R. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061299 · Cited by 16
Sun, Y., Li, H., Guo, Q., Wu, P., Hong, Z., Lü, C., & Wu, Z. (2012) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3182423b6a · Cited by 16
Nanobodies as Structural Probes of Protein Misfolding and Fibril Formation
Genst, E. D., & Dobson, C. M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_34 · Cited by 16
Effect of Cholesterol on the Structure of Networked Water at the Surface of a Model Lipid Membrane
Oh, M. I., Oh, C. I., & Weaver, D. F. (2020) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.0c01889 · Cited by 16
Chow, T. E., Veziris, C. R., Joie, R. L., Lee, A. J., Brown, J. A., Yokoyama, J. S., Rankin, K. P., Kramer, J. H., Miller, B. L., Rabinovici, G. D., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103282 · Cited by 16
“Participants also had available apolipoprotein E (APOE) genetic data, which was used to determine whether they were carriers of at least one copy of APOE*E4, an AD risk allele (Bertram and Tanzi, 2008).”
Long-term Effects of Adolescent Sport Concussion Across the Age Spectrum
Martini, D. N., Eckner, J. T., Meehan, S. K., & Broglio, S. P. (2017) · The American Journal of Sports Medicine · doi:10.1177/0363546516686785 · Cited by 19
He, K., Li, B., Huang, L., Zhao, J., Hua, F., Wang, T., Li, J., Wang, J., Huang, Q., Chen, K., et al. (2023) · European Radiology · doi:10.1007/s00330-023-10366-z · Cited by 15
“This could be due to the early onset of AD [59].”
Ahmed, T. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16336 · Cited by 23
“The siRNA sequences used for AD -associated genes, such as APP, PSEN1, PSEN2, MAPT, APOE, CLU,”
BackgroundInfluentialTargeting Amyloid Pathology in Early Alzheimer’s: The Promise of Donanemab-Azbt
Khartabil, N., & Awaness, A. (2025) · Pharmacy · doi:10.3390/pharmacy13010023 · Cited by 19
“It typically manifests early, with an average age of onset of around 46.2 years and cases reported as early as the 20s [8].”
InfluentialUnraveling the biological mechanisms in Alzheimer's disease — Lessons from genomics
Borovečki, F., Klepac, N., Mück‐Šeler, D., Hajnšek, S., Mubrin, Z., & Pivac, N. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.12.019 · Cited by 17
“Overpast several decades,more than500geneshave been associated with increased risk of AD, mainly by utilizing the candidate gene approach (Bertram and Tanzi, 2008).”
BackgroundProbst, S., Krüger, M., Kägi, L., Thöni, S., Schuppli, D., Nitsch, R. M., & Konietzko, U. (2020) · Journal of Cell Science · doi:10.1242/jcs.242917 · Cited by 19
DRUG DISCOVERY AND DEVELOPMENT: AN OVERVIEW
Sharma, B. (2020) · Indian Research Journal of Pharmacy and Science · doi:10.21276/irjps.2020.7.2.14 · Cited by 17
Wang, J., Wang, M., Ren, S., Huang, L., He, K., Li, J., Hua, F., Guan, Y., Guo, Q., Huang, Q., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221166 · Cited by 18
“:3) plaque burden and tau deposition [38].”
Yu, J., Yang, Y. P., Zhang, W., Wu, Z., Li, Y., Zhang, N., & Tan, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.04.023 · Cited by 15
Liang, F., Wan, Y., Schaak, D., Ward, J. F., Shen, X., Tanzi, R. E., Zhang, C. M., & Quan, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-05619-z · Cited by 16
Self-citationMemory performance and fMRI signal in presymptomatic familial Alzheimer's disease
Braskie, M. N., Medina, L. D., Rodríguez‐Agudelo, Y., Geschwind, D. H., Macías-Islas, M. Á., Thompson, P. M., Cummings, J. L., Bookheimer, S. Y., & Ringman, J. M. (2012) · Human Brain Mapping · doi:10.1002/hbm.22141 · Cited by 18
“However, carriers of rare genetic mutations in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes inherit an early onset form of familial AD (FAD) in a fully penetrant autosomal dominant manner [Bertram and Tanzi, 2008].”
BackgroundTRP Channels in the Brain: What Are They There For?
(2017) · Frontiers in neuroscience · doi:10.1201/9781315152837-17 · Cited by 14
Ma, C., Su, J., Sun, Y., Feng, Y., Shen, N., Li, B., Liang, Y., Yang, X., Wu, H., Zhang, H., et al. (2019) · Angewandte Chemie · doi:10.1002/ange.201912399 · Cited by 14
Self-citationTranscription factor EB as a key molecular factor in human health and its implication in diseases
Gebrie, A. (2023) · SAGE Open Medicine · doi:10.1177/20503121231157209 · Cited by 14
Apolipoprotein ε in Brain and Retinal Neurodegenerative Diseases
Abyadeh, M., Gupta, V., Paulo, J. A., Sheriff, S., Shadfar, S., Fitzhenry, M. J., Amirkhani, A., Gupta, V. B., Salekdeh, G. H., Haynes, P. A., et al. (2024) · Aging and Disease · doi:10.14336/ad.2023.0312-1 · Cited by 28
“Interestingly ApoE has profound effects on regulating Aβ metabolism, tau pathology, mitochondrial function, inflammation and other pathways that play a central role in AD pathogenesis [7, 9, 38, 40, 99, 101, 102] therefore”
Using Synbiotics as a Therapy to Protect Mental Health in Alzheimer's Disease
Ngoc, A. P. T., Zahoor, A., Kim, D., & Yang, S. H. (2024) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.2403.03021 · Cited by 17
“Furthermore, certain genetic factors considerably influence the onset and progression of AD [14].”
BackgroundWomen with the Alzheimer’s risk marker ApoE4 lose Aβ-specific CD4+ T cells 10–20 years before men
Begum, A. N., Cunha, C. D., Sidhu, H., Alkam, T., Scolnick, J., Rosario, E. R., & Ethell, D. W. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.51 · Cited by 16
Tang, S.-S., Wang, H.-F., Zhang, W., Kong, L.-L., Zheng, Z.-J., Tan, M.-S., Tan, C.-C., Wang, Z.-X., Tan, L., Jiang, T., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9819 · Cited by 14
“As to the more common late-onset AD (onset > 65 years; LOAD), only the APOE ε4 has been consistently identified to be a risk factor of the disease [5].”
BackgroundPorcine placental extract facilitates memory and learning in aged mice
Yamauchi, A., Tone, T., Sugimoto, K., Lim, H. S., Kaku, T., Tohda, C., Shindo, T., Tamada, K., Mizukami, Y., & Hirano, E. (2019) · Food Science & Nutrition · doi:10.1002/fsn3.1156 · Cited by 14
“Aging is also a prime risk factor for various diseases and gives rise to a decline in cognitive function through the major forms of neurodegeneration, such as Alzheimer's disease (AD), for which aging is the most significant risk factor (Bertram & Tanzi, 2008).”
BackgroundLorenzi, C., Marcone, A., Pirovano, A., Marino, E., Cordici, F., Cerami, C., Delmonte, D., Cappa, S. F., Bramanti, P., & Smeraldi, E. (2010) · Neurological Sciences · doi:10.1007/s10072-010-0400-8 · Cited by 14
“From genetic point of view, besides the bases of early-onset AD (EOAD), affecting about 5–10% of the population, are relatively well characterized [14, 15], the pathogenesis of the more common late-onset AD (LOAD) is still highly debated [15].”
BackgroundGlaucoma and Alzheimer’s Disease in the Elderly
Bizrah, M., Guo, L., & Cordeiro, M. F. (2011) · Aging Health · doi:10.2217/ahe.11.51 · Cited by 16
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Kayed, R., Castillo-Carranza, D., & Guerrero-Muñoz, M. (2013) · ImmunoTargets and Therapy · doi:10.2147/itt.s40131 · Cited by 14
Yu, J., Mao, C.-X., Zhang, H.-W., Zhang, Q., Wu, Z., Yu, N., Zhang, N., Yang, L., & Tan, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.09.024 · Cited by 14
Role of Nutrition to Promote Healthy Brain Aging and Reduce Risk of Alzheimer’s Disease
Walters, M., Hackett, K., Caesar, E. E., Isaacson, R., & Mosconi, L. (2017) · Current Nutrition Reports · doi:10.1007/s13668-017-0199-5 · Cited by 16
Vogelgsang, J. S., Vukovich, R., Wedekind, D., & Wiltfang, J. (2019) · ASN NEURO · doi:10.1177/1759091419845524 · Cited by 14
“Different functions of APOE have been described within the pathologic pathway of AD (reviewed in Bertram and Tanzi, 2008).”
BackgroundLuo, S., Li, L.-Y., Guo, L.-Z., Wang, L., Wang, Y., Chen, N., & Wang, E. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.978768 · Cited by 15
“AD is characterized by the pathogenesis of extracellular amyloid plaques, neurofibrillary tangles, hyperphosphorylated tau protein, reductions in synaptic density, and neuroimmune activation (Bertram and Tanzi, 2008).”
BackgroundRezaei‐Ghaleh, N., Amininasab, M., Giller, K., & Becker, S. (2023) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c03729 · Cited by 15
Shoukat, S., Zia, M. A., Uzair, M., Alsubki, R. A., Sajid, K., Shoukat, S., Attia, K. A., Fiaz, S., Ali, S., Kimiko, I., et al. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08674-0 · Cited by 15
A variant withinFGF1is associated with Alzheimer's disease in the Han Chinese population
Tao, Q., Sun, Y., Liu, Z., Wang, N., Yang, P., Li, H., Lu, S., & Wu, Z. (2014) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32205 · Cited by 13
Edler, M. K., Johnson, C. T., Ahmed, H. S., & Richardson, J. R. (2020) · The Journal of Comparative Neurology · doi:10.1002/cne.25089 · Cited by 16
Cognitive deficits in human ApoE4 knock-in mice: A systematic review and meta-analysis
van Heuvelen, M. J. G., van der Lei, M. B., Alferink, P. M., Roemers, P., & van der Zee, E. A. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115123 · Cited by 16
“While a small proportion of AD cases is hereditary, the vast majority results from an interplay of genetic and environmental factors [8].”
BackgroundCell-specific copper dyshomeostasis mechanism in Alzheimer’s disease
Okafor, M., Faller, P., & Vitale, N. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00504-6 · Cited by 18
“The highest genetic risk factor in the development of AD is the APOE -ε4 variant [38, 39].”
Zhang, C.-C., Wang, H.-F., Tan, M., Wan, Y., Zhang, W., Zheng, Z.-J., Kong, L., Wang, Z., Tan, L., Jiang, T., et al. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9780-y · Cited by 12
A review on herbal Ayurvedic medicinal plants and its association with memory functions
Gupta, A., Pal, S. M., & Sisodia, S. S. (2018) · The Journal of Phytopharmacology · doi:10.31254/phyto.2018.7210 · Cited by 17
“Many causal reasons appear to be involved in sporadic AD, including aging ([9]), mitochondrial defects ([10]), insulin dependent diabetes ([11,12]), environmental conditions [13] and diet [14, .”
BackgroundFunctional insight into LOAD-associated microglial response genes
Jonas, L. A., Jain, T., & Li, Y. (2022) · Open Biology · doi:10.1098/rsob.210280 · Cited by 16
Does Dementia Have a Microbial Cause?
Landry, R. L., & Embers, M. E. (2022) · NeuroSci · doi:10.3390/neurosci3020019 · Cited by 14
“Unlike the genes associated with the early-onset form, the APOE 4 allele is not deterministic or sufficient to cause AD but rather confers a higher risk for developing LOAD [36,38].”
BackgroundInfluentialCommon variant in GAB2 is associated with late-onset Alzheimer's disease in Han Chinese
Zhong, X.-L., Yu, J., Gui-ying, H., Xing, Y.-Y., Jiang, H. F., Li, Y., & Tan, L. (2010) · Clinica Chimica Acta · doi:10.1016/j.cca.2010.11.022 · Cited by 12
Philibert, K., Marr, R. A., Norstrom, E. M., & Glucksman, M. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00265 · Cited by 12
“AGING NEUROSCIENCE ORIGINAL RESEARCH ARTICLE published: 09 October 2014 doi: 10.3389/fnagi.2014.00265 Identification and characterization of Aβ peptide interactors in Alzheimer’s disease by structural approaches”
BackgroundInfluentialVascular endothelial growth factor polymorphisms and risk of Alzheimer's disease: A meta-analysis
He, D., Lu, W., Chang, K., Yueliang, L., Zhang, J., & Zeng, Z. (2013) · Gene · doi:10.1016/j.gene.2013.01.021 · Cited by 13
Gong, L., Shu, H., He, C., Ye, Q., Bai, F., Xie, C., & Zhang, Z. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.013 · Cited by 14
“The apolipoprotein E (APOE) ε4 allele is a major genetic risk factor that principally influences cognitive function in the preclinical stage of AD, in amnestic mild cognitive impairment (aMCI) (Petersen, 2011; Teipel et al., 2015) and in the dementia stage of late-onset AD (Bertram and Tanzi, 2008).”
BackgroundDahoun, T., Calcia, M., Veronese, M., Bloomfield, P. S., Marques, T. R., Turkheimer, F., & Howes, O. D. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.05.023 · Cited by 16
Association of LRRTM3 polymorphisms with late-onset Alzheimer's disease in Han Chinese
Wang, J., Yu, J., Jiang, T., Tan, M., Wang, H.-F., Tan, L., Hu, N., Sun, L., Zhang, W., & Tan, L. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.01.013 · Cited by 13
“So far, only the ε4 allele of the apolipoprotein E (APOE) gene has been established unequivocally to play a major role in the causation of this disease (Bertram and Tanzi, 2008), but APOE is only approximately 20% of the estimated 80% genetic component, suggesting that numerous additional AD genes may exist.”
Biofilm-Associated Amyloid Proteins Linked with the Progression of Neurodegenerative Diseases
Singh, A. A., Khan, F., & Song, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062695 · Cited by 12
“A β is generated through the cleavage of amyloid precursor protein (APP) by β - and γ - secretases [33]. β”
Ma, X., Yu, J., Wu, Z., Zhang, Q., Liu, Q., Wang, H.-F., Wang, W., & Tan, L. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111847 · Cited by 15
“(cid:1) 4 allele and hyperhomocysteinemia are risk factors for AD [1, 2, 20, 21].”
Ling, C., Fangyu, D., Hu, W., Kelong, C., Wu, Z., Yuting, Z., & Zhou, R. (2015) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317515603688 · Cited by 13
Industrially Scalable Synthesis of Anti-alzheimer Drug Donepezil
Gaonkar, S. L., Nadaf, Y. F., Bilehal, D. C., & Shetty, N. S. (2017) · Asian Journal of Chemistry · doi:10.14233/ajchem.2017.20716 · Cited by 11
Prevention of Alzheimer's Disease in Chinese Populations: Status, Challenges and Directions
Feng, L., Li, J., Yu, J., Zhang, C., Yang, B., Vellas, B. J., & Li, C. (2018) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.14 · Cited by 11
Etnier, J. L., Labban, J. D., Karper, W. B., Wideman, L., Piepmeier, A. T., Shih, C.-H., Castellano, M., Williams, L. M., Park, S.-Y., Henrich, V. C., et al. (2015) · Journal of Aging and Physical Activity · doi:10.1123/japa.2014-0221 · Cited by 13
“Compared with noncarriers, persons with one APOE epsilon 4 (e4) allele have three to four times greater risk (Bertram & Tanzi, 2008; Kapur, Sharad, Kapoor, & Bala, 2006) and those with two APOE e4 alleles have five to 18 times greater risk of AD (Alzheimer’s Association Working Group, 1996).”
Denis, P. A. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.008 · Cited by 13
“Alzheimer’s disease (AD) is the most common neurodegenerative disease, and one of the most common of all diseases in the industrialized world [2].”
BackgroundChang, W., Zhang, L., Jin, Y., & Yao, Y. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0850-7 · Cited by 13
Ren, R., Wang, L., Fang, R., Liu, L., Wang, Y., Tang, H., Deng, Y., Xu, W. L., Wang, G., & Chen, S. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.036 · Cited by 16
“To late, mutations in three genes (APP, PSEN1, and PSEN2) rather than one gene (APOE), which have been observed for late-onset Alzheimer's disease (LOAD), have been identified to be associated with the rare, early-onset, autosomal dominant form of AD [2–4].”
Chaudhary, S., Kaushik, M., Ahmed, S., Kukreti, R., & Kukreti, S. (2018) · ACS Omega · doi:10.1021/acsomega.7b01654 · Cited by 11
Shallie, O. F., & Mabandla, M. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112795 · Cited by 12
Effect of Lycoris chejuensis and Its Active Components on Experimental Models of Alzheimer’s Disease
Kim, J., Park, Y., Chun, Y. S., Cha, J. W., Kwon, H. C., Oh, M. S., Chung, S., & Yang, H. O. (2015) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5b00889 · Cited by 16
Zeng, F., Shen, C., Liu, Y.-H., Li, J., Zhu, J., Wang, Y., Jia-chuan, Y., Gao, C.-Y., Zhou, H., Deng, J., et al. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9516-1 · Cited by 11
Wu, Z., Wu, X., Shen, T., Li, Y., Cheng, X., Gu, L., Huang, Z., & An, L. (2011) · Archiv der Pharmazie · doi:10.1002/ardp.201100188 · Cited by 11
Ward, J. F., Wang, H., Saunders, A. J., Tanzi, R. E., & Zhang, C. M. (2017) · PubMed · Cited by 14
Self-citationLee, J., Mizuno, K., Watanabe, H., Lee, I., Tsumita, T., Hida, K., Yawaka, Y., Kitagawa, Y., Hasebe, A., Iimura, T., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03192-7 · Cited by 17
“As such, the genes involved in the production and process APP, including APP, PSEN1, PSEN2 (components of the ɣ -secretase complex), and BACE1 (β-secretase), have been consistently reported as genetic risk factors for familial AD [4].”
BackgroundShabbir, A., Rehman, K., Akash, M. S. H., Akbar, M., Chaudhary, Z., Panichayupakaranant, P., & Shah, M. A. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20593-4 · Cited by 10
“Cognitive impairments and oxidative stress are strongly associated with one another, as increased accumulation of free radicals causing oxidative insult to biological molecules subsequently results in cognitive deficits and neuronal damage (Bertram and Tanzi 2008).”
BackgroundJain, A., & Roy, P. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.112902 · Cited by 11
The accessible cerebral vascular proteome in a mouse model of cerebral β-amyloidosis
Roesli, C., Fugmann, T., Borgia, B., Schliemann, C., Neri, D., & Jucker, M. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.01.010 · Cited by 10
“The most common form of age-related dementia is Alzheimer's disease (AD) [2].”
BackgroundAmyloid-modifying therapies for Alzheimer’s disease: therapeutic progress and its implications
Creed, M. C., & Milgram, N. W. (2010) · AGE · doi:10.1007/s11357-010-9142-z · Cited by 14
Chun, Y. S., Zhang, L., Li, H., Park, Y., Chung, S., & Yang, H. O. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1023-y · Cited by 10
Predicting clinically promising therapeutic hypotheses using tensor factorization
Yao, J. J., Hurle, M. R., Nelson, M. R., & Agarwal, P. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2664-1 · Cited by 13
Liu, X., Dobbie, M. S., Tunningley, R., Whittle, B., Zhang, Y., Ittner, L. M., & Götz, J. (2011) · BioMed Research International · doi:10.1155/2011/130947 · Cited by 11
“In three genes, autosomal dominant mutations have been identified: amyloid precursor protein (APP), presenilin 1 (PSEN1) as well as presenilin 2 (PSEN2) [14].”
InfluentialParent, A., & Thinakaran, G. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/825918 · Cited by 11
“Both PS1 and PS2 proteins (PS) share about 63% homology with the highest similarity in the transmembrane domains where most of the FAD-linked mutations are found [2, 3].”
BackgroundChoudhary, G. P., Prajapat, M., Kaur, G., Singh, H., Mahendiratta, S., Prakash, A., & Medhi, B. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2274518 · Cited by 10
“This form of AD, known as familial AD, however, only accounts for a small subset of all AD (Bertram & Tanzi, 2008; Johnson et al., 2012; Nelson, 2005; Wenk, 2003).”
Atanasova, M. (2025) · Pharmaceuticals · doi:10.3390/ph18030306 · Cited by 10
“Next, γ -secretase cleaves C99 into A β , which is released from the cell, while the AICD is released into the cytosol (Figure 1) [23,31,32].”
Potential Role of Oxidative Stress in the Pathophysiology of Neurodegenerative Disorders
Singh, S. K., Ahuja, A., & Pathak, S. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073280680240101065732 · Cited by 11
Microheterogeneity of some serum glycoproteins in neurodegenerative diseases
Marklová, E., Albahri, Z., & Vališ, M. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.11.006 · Cited by 9
“Another suspicious locus encodes Tf C2 protein variant, which is a component of AD senile plaques; besides, iron is a major factor in free radical generation [5].”
Presenilin-2 polymorphisms and risk of sporadic AD: Evidence from a meta-analysis
Chen, C., Zhou, Z., Li, M., Qu, M., Ma, Q., Zhong, M., Zhang, Y., & Yu, Z. (2012) · Gene · doi:10.1016/j.gene.2012.05.005 · Cited by 10
“or at least found to be insignificant in some AD populations upon further investigation (Bertram and Tanzi, 2008).”
BackgroundResultInfluentialRole of Antioxidants in Human Health
Manivannan, J., Silambarasan, T., Shanthakumar, J., Suganya, N., & Kanchana, S. (2016) · Springer eBooks · doi:10.1007/978-3-319-40458-5_36 · Cited by 10
Duan, J., Marcellus, K. A., Qin, X., Wang, Y., & Paudel, H. K. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.03.009 · Cited by 9
“Several genetic studies have shown polymorphisms within the human CysC gene linked to the development of late-onset AD (Bertram and Tanzi, 2008; Cathcart et al., 2005; Crawford et al., 2000; Finckh et al., 2000).”
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.